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Introduction: Patient’s response to drug brand is a comprehensive physiological and
psychological effect which might impact the compliance and efficacy of drugs. Whether
the therapeutic outcome altered on patients with brand response after they experience
drug switch is not clear.
Methods: 459 outpatients with mild-to-moderate depression were divided into the
imported (joint venture) drug group and the domestic drug group according to their
current drug application. Two groups of patients were assessed by drug brand preference
questionnaire and medication compliance questionnaire. Patients with brand preference
in imported (joint venture) drugs group received rational use of limited medical resource
and pharmacoeconomics education, and then switched with domestic drug for 8 weeks.
Safety and efficacy were evaluated both before and after the drug switch.
Results: Overall, there were 27% of patients in imported drug group and 35% of patients
in domestic drug group have brand response, respectively. About 2/3 patients in both
groups showed low or no brand response. The compliance was similar in both groups
with no significant difference (6.04 ± 2.08 vs. 4.74 ± 2.13, respectively, P > 0.05). The
efficacy of imported drug group was significantly better than of the domestic drug group.
Correlation analysis showed that in imported (joint venture) drugs group, medication
compliance was closely related with brand response, but negatively correlated with age
and duration. In domestic drugs group, medication compliance was independent of
brand response, but closely related with education, age, and duration. After drug switch
with domestic drug on patients with brand response, patients continued tomaintain good
antidepressant effect, and no severe adverse reaction occurred.
Conclusion: The results suggested that domestic drugs switch might be feasible for
patients using imported drugs with brand response, while providing patients with rational
use of drug education and psychological support. The medical staff should focus on
medication education to help patients make better use of limited medical resources.
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INTRODUCTION
Patient’s response to treatment is a comprehensive physiological
and psychological effect (Moerman, 2002, 2006; Moerman and
Jonas, 2002). The treatment covers very wide, from drug brand,
dosage forms, preparation color, the amount of oral tablet or
capsule, injection volume, to health professionals’ appearance,
manner, behavior, facial expression and tone of voice. In China,
since we have a large number of drug manufactures, there are
thousands of drugs available covering domestic drug, imported
(joint venture) dugs, as well as originators. Usually we refer to
imported (joint venture) dugs and originators as brand drugs,
while domestic drugs are generics (Huttin, 1994; Sun et al., 2008).
Our studies have found that drug brand responses can impact
on drug selection and adherence (Wang et al., 2010; Cao et al.,
2011). Besides, due to the brand recognition and expectation,
when Chinese patients were switched from domestic drug (i.e.,
generics) to imported (joint venture) drugs, they usually reported
a better drug efficacy (Ge and Zhu, 2007). However, as a vast,
whether in unbalanced developed countries or in low-to-middle
income countries, the medical resource is limited (Xu, 1990; Huo
et al., 2016). We cannot offer all patients with imported (joint
venture) drugs nor should we with good quality domestic drug.
It is of importance to rational use the limited medical resource
in China (Gao et al., 2011; Jin et al., 2015; Liu et al., 2016).
Consequently, domestic drug prescribing is encouraged by all
levels of government. In this work, we reported the efforts that
encourage patients with brand response to use domestic drugs
rather than imported (joint venture) drugs, aiming to provide
some useful information for rational drug use.
PATIENTS AND METHODS
Patients
Patients with a diagnosis of mild-to-moderate depression in
Fengxian Mental Health Center were recruited. The inclusion
criteria included a requirement that patients have the ability
of reading and understanding, have consciousness during the
survey and are willing to participate in this investigation. The
demographic information was collected including gender, age,
education, course of treatment, and current drug application.
The protocol was approved by Fengxian Hospital’ Institutional
Review Committee.
Questionnaire
The questionnaire included brand responses and medication
compliance. Brand response questionnaire consists of five
questions (Wang et al., 2010): (1) You prefer to use domestic
drugs because they are safe, effective, low side-effects, and
economic? (2) You prefer to use imported (joint venture) drugs
because they are safe, effective, low side-effects, and economic?
(3) Do you think domestic drugs are equivalent to imported
(joint drugs)? (4) Is it OK if you switch from domestic drugs
to imported drugs? (5) Is it OK if you switch from imported
drugs to domestic drugs? All questions have score standard: 2
for “agree,” 1 for “uncertain,” 0 for “disagree.” While the score
of question 1, 3, and 5 was reversed. The total score points
ranged from 4∼0. Patients with 4 points were considered as
brand response. Patients with 3∼1 points were considered as
low brand response. Patients with 0 point were considered as no
brand response. The self-made questionnaire has good reliability
and validity and had been used in China (Wang et al., 2010; Cao
et al., 2011)
General medication compliance questionnaire was conducted
according to compliance questionnaire (Chinese-version) (Zhao
et al., 2002; Xie et al., 2013). The total score ranged from 0 to
11 points. Patients with a high score indicated better medication
compliance.
Drug Switch
In order to observe the impact of drug switch from imported
(joint venture) drugs to domestic drugs on safety and efficacy,
patients who currently used imported (joint venture) drugs and
displayed brand response (4 points) were recruited for further
study. It is an open, quasi single-arm test without any parallel
control but with self-control. The patients provided written
informed consent (a few patients gave oral informed consent),
and then were offered medical evidence on bioequivalence
between imported drugs and domestic drugs, and explained
the significance of pharmacoeconomics in this limited medical
resource country. According to patients’ condition and follow-
up frequency, patients divided into three groups, were given
domestic drugs to replace corresponding imported drugs for 8
weeks. The drug switch program was free of charge. During
the switch period, physician follow-up was given once a week,
20 min for each time. In the follow-up course, patients were
reviewed carefully, strengthened by rational drug use education
and provided with psychological support. The safety and
efficacy were evaluated before and after the 8-week switch.
Adverse drug reactions were reported to investigators at any
time.
Safety/Adverse Reaction Report
Adverse drug reaction was evaluated by Treatment Emergent
Symptom Scale (TESS). Appropriate measures were ready to deal
with any reaction if necessary.
Efficacy
Hamilton Depression Scale (HAMD) was used to assess the
efficacy (Lai et al., 2015). HAMD contains 24 items, most of the
items scores from 0 to 4 point in 5 levels as follows: absent (0
point), mild (1 point), moderate (2 point), severe (3 points), and
very severe (4 point). The total score of 0∼7 is considered to
be normal, 8∼20 is suspected to have mild depressive symptom,
20∼30 is considered to be depression, and >35 indicates severe
depression.
Statistical Analysis
The SPSS for Windows 19.0 software (SPSS Inc., Chicago, IL,
USA) was used for all data analysis. Quantitative variables
were described as mean ± SD, while qualitative variables were
expressed as number and percentage. Statistical significance was
assumed at the P < 0.05 level.
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RESULTS
Patient Demographic Information and
Brand Response
A total of 468 outpatients, aged between 12 and 80 years old, with
a diagnosis of mild-to-moderate depression, were enrolled in the
present study. Nine patients were excluded due to loss to follow-
up. Finally 459 patients participated in and finished the program
(Table 1). Sixty-nine of the 256 patients (27%) currently used
imported (joint venture) drugs showed brand response. Seventy-
two in 203 patients (35%) patients currently used domestic drugs
showed brand response. No statistically significant difference
existed between 2 groups for brand response (Figure 1).
In two groups, patients displayed ascending brand response
since treatment beginning, but gradually no longer response after
a long time of medication (Figure 2).
Brand Preference and Compliance
In general, the medication compliance of patients is acceptable.
The compliance of patients in imported drugs group was similar
to that in domestic drugs group (6.04 ± 2.08 vs. 4.74 ± 2.13,
P > 0.05). Among the patients in imported drugs group, the
compliance of patients with brand response was the best (6.30
± 1.93). However, patients with brand response in domestic
group did not have such optimal compliance (4.63 ± 1.94)
(Table 2). Correlation analysis showed that the compliance was
positively related with brand response in the imported drugs
group. However, compliance was negatively related to age, course
of treatment both in the imported drugs group and in the















Female 236 75 142 93
Male 223 66 114 110
AGE
<30 years 47 10 29 18
30–60 years 306 89 176 130
>60 years 106 42 51 55
EDUCATION
Low 198 81 73 125
Middle 202 54 139 63
High 59 6 44 15
ALCOHOL
Every day 2 0 1 1
Often 26 8 16 10
Sometimes 155 49 79 76
Never 276 84 160 116
SMOKE
Yes 128 43 67 61
No 331 98 189 142
domestic drugs group. Yet compliance was related to education
in domestic drugs group (Table 3).
Drug Switch Efficacy
Sixty patients with brand response in imported drugs group
were given rational drug use and pharmacoeconomics education.
Their informed consent was obtained and they were provided
corresponding domestic drugs (free of charge) for 8 weeks.
Patients were divided into 3 groups according to the course
of treatment. Before drug switch, patients’ HAMD scores had
no significant difference among the 3 groups. After 8 weeks of
drug switch treatment, the HAMD score of 3 groups declined.
However, the declines in patients in 2 groups with less than
10 years medication were statistically significant (P < 0.05). In
general all patients with brand response continued to maintain
good antidepressant activity when switched to domestic drugs
switch (Table 4).
Safety and Adverse Drug Reaction
During the 8-weeks domestic drugs switch treatment, suspicious
or very slight adverse reactions were reported sporadically in
60 patients. Before switch, the main adverse reactions were
thirst, constipation, sweating, insomnia, increased saliva, reduced
activity, weight gain, nasal congestion, dizziness, and vertigo.
After switch, the adverse reactions were almost the same. No
moderate or severe adverse events were found during the switch.
DISCUSSION
Many patients display brand response both in high-earning
patients and in low-income patients in China due to their
blind brand worship and low health literacy (Cai et al., 2013;
Xiao and Xu, 2014). Patients and their family members usually
worry about safety, efficacy and quality of the generics. As to
non-patient factors, the choice of imported drugs or domestic
drugs has always been a challenge both in medication and in
economics. Many physicians and hospitals relied on the profits
from drug procurement for an appreciable proportion of their
income—so not in their interests to prescribe/dispense low cost
domestic drugs and persuade patients of the benefits of the
imported (joint venture) drugs—leading to a strong placebo like
effect(Reynolds and McKee, 2011; Li et al., 2012; Zeng et al.,
2014). The competition between brand-name drugs and generics
is becoming fiercer than ever before in the world, especially
with the increase of newly approved generics in developing
countries. Although domestic drugs (i.e., generics) have been
verified bioequivalence to the originator (imported-joint venture
drugs) in many published studies (Paton, 2006; Sakshaug et al.,
2007; Kesselheim et al., 2008, 2010; Corrao et al., 2014a,b; Gagne
et al., 2014; Lessing et al., 2014; Martin et al., 2014), quite a lot of
patients in China still prefer brand-name drugs. Compared with
the situation in China, foreign countries have different attitudes
to generic drugs. In the Scotland, there are very high voluntary
INN prescribing antidepressants exist (Godman et al., 2013a). In
Sweden, the vast majority of physicians agree that they should
prescribe generic drugs when available, meanwhile, they accept
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FIGURE 1 | Distribution of drug brand response in patients with depression.
FIGURE 2 | Brand response with the different course of treatment (year) in two groups. (A): imported drug group, (B): domestic drug group.
TABLE 2 | Compliance in different brand response patients in the two groups.
Items Imported drugs (n = 256) Domestic drugs (n = 203)
No response Low response Response No response Low response Response
Compliance self-assessment 2.10 ± 0.61 2.16 ± 0.54 1.93 ± 0.60 2.15 ± 0.48 2.11 ± 0.61 1.97 ± 0.73
Forget to take drugs sometimes 0.43 ± 0.50 0.57 ± 0.50 0.74 ± 0.44 0.32 ± 0.47 0.28 ± 0.45 0.28 ± 0.45
Forgot to take drugs in the past 2 weeks 0.83 ± 0.38 0.88 ± 0.32 0.88 ± 0.32 0.88 ± 0.33 0.68 ± 0.47 0.61 ± 0.49
Self determine to reduce dosage or withdraw drugs
w/o inform physicians
0.66 ± 0.48 0.71 ± 0.45 0.80 ± 0.41 0.56 ± 0.50 0.47 ± 0.50 0.68 ± 0.47
Take no drugs when travel 0.03 ± 0.18 0.04 ± 0.19 0.00 ± 0.00 0.00 ± 0.00 0.03 ± 0.18 0.06 ± 0.23
Forgot to take drug yesterday 0.03 ± 0.18 0.01 ± 0.09 0.03 ± 0.17 0.02 ± 0.16 0.06 ± 0.23 0.07 ± 0.26
Stop taking drugs by oneself as feel better 0.57 ± 0.50 0.73 ± 0.45 0.81 ± 0.39 0.56 ± 0.50 0.40 ± 0.49 0.54 ± 0.50
Feel difficult to adhere treatment for chronic diseases 0.40 ± 0.49 0.50 ± 0.50 0.54 ± 0.50 0.39 ± 0.49 0.29 ± 0.46 0.22 ± 0.42
Feel difficult to follow regimen 0.47 ± 0.50 0.55 ± 0.50 0.58 ± 0.58 0.37 ± 0.49 0.29 ± 0.46 0.19 ± 0.40
Total 5.52 ± 2.47 6.14 ± 1.94 6.30 ± 1.93 5.24 ± 2.28 4.60 ± 2.20 4.63 ± 1.94
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TABLE 3 | Correlation between compliance with gender, age, education,






Brand response 0.26* 0.00





Brand response 0.04 0.60
Course of treatment −0.24* 0.03
*Correlation is significant at the 0.01 level (2-tailed).
TABLE 4 | Efficacy (HAMD score) after drug switch in 60 patients with
brand response.
Course of treatment Before switch After switch P-value
1–3 years (n = 30) 17.67 ± 4.093 11.08 ± 5.030 0.000
4–10 years (n = 22) 15.69 ± 3.478 10.75 ± 5.447 0.013
>10 years (n = 8) 15.50 ± 1.000 11.00 ± 4.889 0.135
Total 16.75 ± 3.780 10.95 ± 5.058 0.000
compulsory generic substitution including antidepressants as
well (Andersson et al., 2006; Godman et al., 2013b).
Long term adherence is a real issue across products (Cramer
et al., 2008). It is interesting to note that the medication
compliance is almost the same regardless imported drugs use
and domestic drugs use in this study, which is similar to many
evidences. In fact, generics actually aid long term compliance
as more economical in developed countries (Shrank et al.,
2006; Simoens and Sinnaeve, 2014; Barbui and Conti, 2015).
In United States the vast majority (83%) agreed that physicians
should prescribe generic drugs when available, however, non-
Caucasian has higher brand-name drug response than Caucasian
and holds much skeptical attitude to the efficacy and safety of
generics (Kesselheim et al., 2016). A survey conducted in Poland
showed that about 3/4 of patients preferred to use generic drugs.
Poland has one of the highest utilization rates for generics in
Europe driven by domestic manufacturing and patients paying
the price difference between the generic and a brand-name
drug in a class (Drozdowska and Hermanowski, 2015). People’s
attitude to generics is often influenced by their physicians,
pharmacists, family, friends, mass media and their health literacy.
Pharmacists, as professionals, were more willing to use generics
rather than brand-name drugs for self-management of common
health problems due to their professional knowledge and health
literacy (Patel et al., 2016). Unfortunately, there are a number of
publications that have shown concerns with generics, which have
impacted on their use (Van Ameringen et al., 2007; Margolese
et al., 2010; Pae et al., 2010; Desmarais et al., 2011; Cessak et al.,
2016).
The data in this work confirmed that about 30% of patients,
no matter what class of drugs they use currently, have brand
response. We also found that patient’s brand response gradually
declined as the treatment course extended. It may be due to
the psychological fatigue induced by the long term medication
course. Patients may not be as sensitive as at the beginning of
treatment.
Medication compliance of patients in imported drugs group
was positive correlated with brand response, however, no similar
relationship occurred in domestic drugs group. The hidden
reason for the difference is not clear. In general, medication
compliance in the 2 groups was negatively correlated to age and
course of treatment, suggesting we should pay more attention to
elderly patients with long time medication.
According to our study, we found that as long as we
provided rational drug use information, therapeutic equivalence
evidences, pharmacoeconomics education and psychological
support, patients even with brand response might be successfully
switched to domestic drugs that might effectively save medical
resource. In addition, providing the medicines free of charge
might be one of the factors for the smooth switch, with
published studies showing co-payments do influence the use
of antidepressants (Barbui and Conti, 2015). Our results at
least suggested that domestic drugs might replace the imported
drugs with their acceptable safety and efficacy. Patients have
right to choose domestics drugs or imported drugs depending
on their economic situation, however, if our efforts help
enhance the rational use of medical resource, the world will be
better.
CONCLUSION
Brand responses may benefit medication compliance in patients.
With rational drug use education and psychological support,
patients may be switched to generics to save limited medical
resource in developing countries.
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